Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3025]

Maintenance therapy with PARP inhibitor olaparib delays progression in patients...

Dr Hedy Kindler - University of Chicago, Chicago, USA

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer ( Dr Hedy Kindler - University of Chicago, Chicago, USA )

Comment: It is essential to identify the BRCA gene in pancreatic cancer...

Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent ( Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA )

PARP inhibitors are a promising alternative to chemotherapy for patients with...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Comment: Reasonable to conclude that pembrolizumab is non-inferior to...

Dr Richard Schilsky and Dr Josep Tabernero

Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy ( Dr Richard Schilsky and Dr Josep Tabernero )

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or...

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona...

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain )

Comment: The success of immunotherapy means we have to change our mindset as we...

Dr David Graham and Dr Edward B. Garon

Comment: The success of immunotherapy means we have to change our mindset as we treat patients ( Dr David Graham and Dr Edward B. Garon )

Pembrolizumab is safe and effective and substantially increases overall...

Dr Edward B. Garon - UCLA, Los Angeles, USA

Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients ( Dr Edward B. Garon - UCLA, Los Angeles, USA )

Latest in ovarian cancer treatment

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Latest in ovarian cancer treatment ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Bladder Problems following ovarian cancer treatment

Ellie Stewart - Guy’s and St Thomas NHS Foundation Trust, London, UK

Bladder Problems following ovarian cancer treatment ( Ellie Stewart - Guy’s and St Thomas NHS Foundation Trust, London, UK )

Highlights from ICALL 2019

Prof Hervé Dombret - University Paris Diderot, Paris, France

Highlights from ICALL 2019 ( Prof Hervé Dombret - University Paris Diderot, Paris, France )

Prof Anders Bjartell discusses the data sources and access of the PIONEER data...

Prof Anders Bjartell - Skåne University Hospital, Malmö, Lund University, Sweden

Prof Anders Bjartell discusses the data sources and access of the PIONEER data models ( Prof Anders Bjartell - Skåne University Hospital, Malmö, Lund University, Sweden )

More from ecancer